ArticlePloS one2026
A 3-dimensional Resnet model for assessment of drug efficacy in 3D cancer models using optical coherence tomography.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ninety percent of drugs fail during clinical trials, mainly due to lack of clinical efficacy. Recent developments in in vitro models such as 3D tumor heterospheroids have led to improvements in failure rates, but the relative lack of standardized evaluation methods for 3D cultures limits their utility in high-throughput screening. Optical coherence tomography (OCT) shows significant promise for high-throughput screening of 3D models; however, the optimal classification model and key image features for assessing drug efficacy in OCT images of spheroids has yet to be explored in detail. In this study, we investigate whether OCT combined with machine learning methods can be used to identify biomarkers of drug efficacy in 3D tumor spheroid models. We further compare the performance of two different models to determine the optimal configuration for accurate classification. Volumetric OCT images were acquired of co-cultured HT29 spheroids treated with 3 different concentrations of cisplatin. A two-dimensional multi-view ResNet model and a three-dimensional ResNet model were used to classify the images and to identify key image features associated with each group. Differences between spheroids treated with different concentrations of cisplatin are clearly visible in the OCT images. Our model was able to classify the images based on cisplatin concentration with 71.9% accuracy using the 2D multi-view model and 91.2% accuracy using the 3D model. Key features in the 3D model significantly improved the model accuracy. These results underscore the possibility that OCT could be used for high-throughput screening of drugs using 3D in vitro models and highlight key identifying features for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.